For a patient, a cancer diagnosis often means a serious change in his or her life. In addition to the uncertainty as to how the disease will progress, the treatment is extremely stressful. This increases the importance of developing new methods through research that both personalize the therapy and make the treatment more pleasant for the patient. Our device optimizes the way of monitoring results through extreme precise supervision of the healing process of cancer patients. We achieve this with the help of the Heat Shock Protein HSP70. Compared to healthy people, cancer patients have a higher concentration of HSP70. At the Chair of Experimental Radiooncology and Radiobiology of Prof. Multhoff (TUM), antibodies are being researched that specifically bind to the HSP70 protein. In the further course of the process, radiation in the visible range is emitted, which we measure with extremely sensitive silicon photomultipliers. These components are able to detect single photons. The intensity of the radiation is therefore measures the amount of heat shock proteins found in the blood. This quantity correlates to a certain extent with the Number of cancer cells in the body. At present, there is no automated solution for measuring HSP70 concentrations. Our approach is therefore to monitor the effectiveness of the cancer treatment as well as the exact healing process of the patient by means of repeated blood analyses of the patient.